Pancreatic cancer vaccine shows early trial safety

·

·

1–2 minutes

Summary

A small Johns Hopkins trial found an experimental pancreatic cancer vaccine appeared safe and triggered immune responses in high-risk patients.

Why this matters

Pancreatic cancer is often hard to detect early, so research into prevention for high-risk people could expand options beyond monitoring alone. The findings remain preliminary and will need larger studies to test whether the vaccine reduces cancer risk.

An experimental vaccine aimed at preventing pancreatic cancer showed signs of immune activity and appeared safe in a small phase 1 trial at Johns Hopkins School of Medicine in Baltimore, according to a study published in Cancer Discovery.

The trial tested mKRAS-VAX in 20 people with an inherited risk of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, and an abnormality found on imaging, usually a pancreatic cyst. None had been diagnosed with pancreatic cancer.

Participants received four injections during weeks 1, 3, and 5, with a booster at week 13. The vaccine targeted six common KRAS mutations, which researchers said drive more than 90% of pancreatic ductal adenocarcinomas.

Researchers reported that 18 of 20 participants, or 90%, developed a mutant KRAS-targeted immune response. On average, immune activity increased about 18-fold, though responses varied. Half of participants responded to all six KRAS mutations included in the vaccine.

The study also found the vaccine generated two types of T cells, one to attack abnormal cells and one associated with longer-term immune memory.

Researchers said the vaccine appeared safe. Reported side effects were limited to injection-site reactions and temporary flu-like symptoms.

The phase 1 trial was designed primarily to evaluate safety, not effectiveness. After about 16.5 months of follow-up, no participants had developed pancreatic cancer. Researchers also reported that 37.5% of vaccinated participants had shrinkage or disappearance of the pancreatic cysts linked to increased risk.

“In addition, the vaccine was safe and well-tolerated, supporting its use in larger cancer interception studies,” study co-author Dr. Neeha Zaidi, an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, said in a press release. “Overall, this study represents the first proof of concept for the use of vaccines for interception of pancreatic cancer in human patients.”

  • Houthis claim Red Sea tanker strikes amid Iran conflict

    Iran also said two people were killed in a U.S. missile strike near the passenger terminal at the Shalamcheh border crossing with Iraq.

    Full story +

  • U.S., Saudi Arabia sign civilian nuclear pact

    The two sides also signed a separate bilateral safeguards agreement.

    Full story +

  • Trump says U.S. could strike Iran’s Pickaxe Mountain

    Defense Secretary Pete Hesgseth said the Iran war had cost the United States $37.5 billion.

    Full story +

  • Trump threatens strikes on Iran infrastructure

    The U.S. has already bombed bridges in southern Iran over the last 11 days of fighting. Strikes on power plants or in Tehran would mark a further escalation.

    Full story +

  • U.S. strikes Iran again; Tehran fires hit Jordan

    Iran’s Health Ministry said U.S. strikes over the past 11 days had killed 53 people, including six women and three children, and wounded nearly 600.

    Full story +

  • OpenAI says AI model hacked Hugging Face systems

    OpenAI said it was “an unprecedented cyber incident.”

    Full story +

  • EU clears Paramount-Warner deal, sets conditions

    The merger still faced legal challenges in the United States.

    Full story +

  • ,

    Florida man sues OpenAI over ChatGPT medical advice

    A February study in Nature found that physicians evaluating ChatGPT Health said it often gave poor medical advice, especially in emergencies.

    Full story +

  • Pancreatic cancer vaccine shows early trial safety

    The authors said the study was limited by its small size and because it was not designed to determine clinical efficacy.

    Full story +

  • Report: Virginia gas costs rose $1.8B since war

    Lawmakers have proposed several gas relief measures.

    Full story +